Izabela Gulbas, Adrian Bekier, Adrian Gajewski, Mateusz Gawrysiak, Sylwia Michlewska, Magdalena Chmiela, Maciej Chałubiński
{"title":"Rhinoviral Infection of the Human Lung Vascular Endothelium May Protect From the Secondary Infection With Rhinovirus RV-16","authors":"Izabela Gulbas, Adrian Bekier, Adrian Gajewski, Mateusz Gawrysiak, Sylwia Michlewska, Magdalena Chmiela, Maciej Chałubiński","doi":"10.1111/apm.70011","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Rhinoviruses are a major cause of respiratory infections, including asthma infectious exacerbations. Human rhinovirus 16 (RV-16) has been widely shown to infect respiratory epithelial cells and the human lung vascular endothelium. RV-16 was also observed to induce an IFN-β-dependent mechanism of antiviral intracellular mechanisms based on OAS-1 and PKR activity. This study aimed to investigate whether the human lung microvascular endothelial cells (HMVEC-L) infected with RV-16 display a resistance to subsequent infections with the same virus, RV-16. HMVEC-L were infected with RV-16 and reinfected with RV-16 on Day 5. IFN-β-dependent responses, antiviral protein expression, inflammatory cytokine levels, and a viral copy numbers were assessed by real-time PCR, flow cytometry, ELISA, and confocal microscopy. RV-16 infection induced a significant IFN-β production and an activation of IFN-β-dependent antiviral proteins in HMVEC-L. On Day 5 post infection, these antiviral mechanisms remained active. In cells reinfected with RV-16, significantly lower replication of RV-16 was observed as compared to cells primarily infected with RV-16 on Day 5. Concomitantly, reinfected HMVEC-L showed a weaker response in IFN-β and inflammatory cytokine production. HMVEC-L infected with RV-16 display a sustained activation of IFN-β-dependent antiviral mechanisms, conferring resistance to subsequent infections with RV-16.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"133 3","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rhinoviruses are a major cause of respiratory infections, including asthma infectious exacerbations. Human rhinovirus 16 (RV-16) has been widely shown to infect respiratory epithelial cells and the human lung vascular endothelium. RV-16 was also observed to induce an IFN-β-dependent mechanism of antiviral intracellular mechanisms based on OAS-1 and PKR activity. This study aimed to investigate whether the human lung microvascular endothelial cells (HMVEC-L) infected with RV-16 display a resistance to subsequent infections with the same virus, RV-16. HMVEC-L were infected with RV-16 and reinfected with RV-16 on Day 5. IFN-β-dependent responses, antiviral protein expression, inflammatory cytokine levels, and a viral copy numbers were assessed by real-time PCR, flow cytometry, ELISA, and confocal microscopy. RV-16 infection induced a significant IFN-β production and an activation of IFN-β-dependent antiviral proteins in HMVEC-L. On Day 5 post infection, these antiviral mechanisms remained active. In cells reinfected with RV-16, significantly lower replication of RV-16 was observed as compared to cells primarily infected with RV-16 on Day 5. Concomitantly, reinfected HMVEC-L showed a weaker response in IFN-β and inflammatory cytokine production. HMVEC-L infected with RV-16 display a sustained activation of IFN-β-dependent antiviral mechanisms, conferring resistance to subsequent infections with RV-16.
期刊介绍:
APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.